Merck Digital Sciences Studio Montreal Expansion Debuts MDSS

The Merck Digital Sciences Studio Montreal expansion marks Merck’s first MDSS studio outside the United States and Canada, with Montreal serving as a new hub for digital biopharma innovation. On June 20, 2025, Merck announced the opening of the MDSS in Montréal, a collaborative startup accelerator designed to invest in, support, and mentor biopharmaceutical startups focused on cutting-edge digital technologies. The program is geared toward innovations spanning preventive health, platforms for biologics research and development, and 3D translational disease models, and it is part of Merck’s broader strategy to accelerate digital health and AI-enabled drug discovery. (merck.ca)

The Montreal studio launched in July 2025 as a six-month acceleration track open to startups incorporated in Québec or Canada. Seven selected startups joined the cohort, gaining access to mentoring from Merck experts and from Centech, the operating partner for MDSS, along with funding provided through the Merck Global Health Innovation Fund and the CQDM or Merck Canada. This launch also included strong governmental and ecosystem support in Quebec, highlighted by funding commitments to underpin the initiative. The event underscored Merck’s intent to build a robust, cross-border innovation corridor that connects Canadian and North American talent with Merck’s global capabilities. (merck.ca)

In a related development, Merck later expanded MDSS with a second innovation cohort in Montreal, signaling a deeper North American push for digital health progress. On March 13, 2026, Merck announced that the second cohort would begin in March 2026, featuring a nine-month acceleration program for a mix of Canadian and U.S. startups. Twelve startups were selected for this cohort, with mentoring provided by Merck and Centech, and each startup eligible to receive a total of $100,000 USD in funding from the Merck Global Health Innovation Fund, The Venture Collective (TVC), and CQDM. The program’s aim is to build an integrated, cross-border ecosystem in Montreal that accelerates translation from concept to patient impact. (merck.com)

Opening

• Merck, known as MSD outside the United States and Canada, announced the Montreal expansion of its Merck Digital Sciences Studio (MDSS) on June 20, 2025, positioning Montreal as a strategic node for digital biopharma innovation. The MDSS in Montréal focuses on digital technologies across preventive health, biologics R&D platforms, and 3D translational disease models, inviting Canadian startups to participate in a six-month accelerator. Seven startups were selected for the initial cohort, and participants receive mentorship from Merck and Centech, with funding channeled through Merck’s health innovation funds or CQDM and Merck Canada. The Quebec government supported the effort with dedicated funding, underscoring public policy alignment with private-sector innovation. (merck.ca)

• The first cohort’s line-up included Nanofacile, Simmunome, Misochip, 9Bio, Rime Therapeutics, Stereo Bio, and PCare+. This multi-faceted program anchored by MDSS’s collaboration with Centech demonstrates a concrete, place-based strategy to grow digital health capabilities in Montréal while linking local startups to Merck’s global network. The government co-funding and the explicit sector focus illustrate how the program is designed to translate digital science into patient impact. (merck.ca)

• The second cohort’s announcement expands the footprint to a nine-month acceleration and brings a cross-border mix of 12 startups from Canada and the United States. This expansion reinforces the Montréal ecosystem’s role as a cross-border innovation bridge and signals a longer-term commitment to integrating Canadian and North American digital health and AI venture activity under a single MDSS umbrella. The nine-month timeline, coupled with a staged funding model, points to a more mature, scalable program architecture. (merck.com)

What Happened

Announcement details and program structure

• The MDSS Montreal expansion was publicly introduced on June 20, 2025, with Merck confirming a new accelerator in Montréal intended to accelerate biopharmaceutical startups that leverage digital technologies. The program targets three core areas—preventive health, platforms for biologics R&D, and 3D translational disease models—and is designed to provide a structured six-month acceleration for seven selected startups. Access to mentorship from Merck experts and Centech, plus funding from Merck’s health innovation funds or CQDM and Merck Canada, forms the core of the program’s value proposition. The presence of Quebec’s government funding is cited as a key enabling factor. (merck.ca)

• The initial cohort’s seven startups span a range of digital biology and AI-enabled health solutions, illustrating the program’s breadth within digital biopharma: Nanofacile, Simmunome, Misochip, 9Bio, Rime Therapeutics, Stereo Bio, and PCare+. This lineup demonstrates MDSS Montréal’s willingness to invest in early-stage ventures with strong potential to blend computational methods and biologics innovation, a core theme of Merck’s digital science strategy. (merck.ca)

• The government of Québec contributed funding to MDSS Montréal, reflecting public-sector engagement in catalyzing biotech-digital innovation. This support aligns with the province’s broader Life Sciences Strategy and the region’s emphasis on AI and biotech entrepreneurship. The announcement explicitly notes that Québec government funding is part of the MDSS Montréal initiative. (merck.ca)

Second era and program expansion

• On March 13, 2026, Merck announced the second MDSS cohort in Montréal, representing a deliberate expansion of the program into a North American, cross-border platform. The second cohort begins in March 2026 and is described as a nine-month acceleration featuring a mix of Canadian and U.S. startups. Twelve startups participate, with mentors from Merck and Centech guiding them through the program. Each startup may receive a total of $100,000 USD in funding from the Merck Global Health Innovation Fund, The Venture Collective (TVC), and CQDM. The announcement emphasizes a strengthened cross-border collaboration and a Montreal-based hub for AI, life sciences, and technology. (merck.com)

• The second cohort’s Canadian participants include Neiges Biotech, DropGenie, Epiloid Biotechnology, NuvoBio, Modulari-T Biosciences, and Focai, while U.S. startups include ExteRNA, Intero Biosystems, Fletcher Biosciences, Forecast Bio, and Whelix. This cross-border roster underscores MDSS Montréal’s role as a conduit between Canadian and U.S. startup ecosystems, with potential for joint pilots and investment activity that could accelerate product-to-patient timelines. (merck.com)

• The Montreal expansion is framed as a strategic bridge, connecting Canada’s AI and biotechnology capabilities with Merck’s global health innovation network. David Rubin, MD of Merck Global Health Innovation Fund, frames the second cohort as evidence of the ecosystem’s strength and the potential to reshape how medicines are discovered and developed. Other quotes from Merck Canada and CQDM leaders highlight Québec’s leadership in biopharma and AI innovation and the broader North American expansion momentum. (merck.com)

• Independent ecosystem coverage confirms MDSS’s role in Montréal as a signal event for the region’s life sciences and technology environment. Montréal International notes MDSS’s positioning as Montreal’s first MDSS studio outside the United States and highlights the program’s focus on seven Greater Montréal startups in its first phase, underscoring the city’s readiness to host cross-border collaborative endeavors. (montrealinternational.com)

Why It Matters

Regional innovation and ecosystem effects

• MDSS Montréal represents a landmark milestone for the city and the province because it formalizes Montréal’s status as a cross-border hub for biopharma and AI. The program’s emphasis on predictive AI, digital health, and biologics modeling aligns with Québec’s strengths in AI and life sciences, and it benefits from partnerships with Centech and CQDM. The Montreal International coverage stresses that MDSS is a leader in Canada’s health-tech ecosystem and serves as a conduit between Canadian and U.S. innovators. (montrealinternational.com)

• The cross-border structure invites a broader talent and capital flow, potentially accelerating startups from concept to clinical validation and commercialization. By uniting Canadian and U.S. startups within a single program, MDSS Montréal becomes a model for regional collaboration, reducing the friction often associated with cross-border funding, mentorship, and market access. This cross-pollination is reinforced by Merck’s funding partnerships with a spectrum of players, including The Venture Collective and CQDM, which widen the network accessible to MDSS participants. (merck.com)

Impact on startups and venture funding dynamics

• The second cohort’s funding allocation—$100,000 USD total per startup, supported by major partners—signals a meaningful investment scale for early-stage digital health and AI-enabled biopharma ventures. This structure provides startups with early-stage capital, structured mentorship, and exposure to Merck’s decision-makers, potentially catalyzing follow-on investments, pilots, or strategic collaborations. The combination of Merck’s Global Health Innovation Fund, TVC, and CQDM as funding sources is notable for the breadth of capital and expertise it mobilizes. (merck.com)

• The involvement of CQDM and the Quebec government demonstrates how regional public-private partnerships can accelerate early-stage life sciences and AI ventures. The Quebec government’s funding, alongside industry partnerships, also positions MDSS Montréal as a proven model for aligning policy incentives with industry accelerators to scale Canadian health-tech startups. (montrealinternational.com)

Strategic significance for Merck and the broader market

• MDSS Montreal’s expansion aligns with Merck’s broader strategy to fuse life sciences with digital technology, leveraging AI, computational biology, and data science to accelerate drug discovery and development. The second cohort’s cross-border composition and nine-month program design reflect a more mature approach to incubating and scaling digital health innovations within Merck’s global innovation network. Quotes from Merck executives emphasize the program’s potential to create an integrated North American ecosystem that moves ideas from concept to patient impact more quickly. (merck.com)

• Neutral observers and ecosystem partners view MDSS as a signal that Montreal and Québec can play a leading role in AI-enabled life sciences, with the MDSS model potentially serving as a blueprint for other regions seeking to attract global pharma interest and cross-border startup activity. Montreal International’s coverage highlights MDSS’s status as a noteworthy cross-border accelerator and its role in strengthening Montréal’s life sciences and AI clusters. (montrealinternational.com)

What’s Next

Timeline and upcoming milestones

• The first MDSS Montréal cohort began in July 2025 and ran for six months, culminating in a demonstration of the startups’ progress and potential for long-term collaborations with Merck’s network. The initial cohort’s seven companies gained access to mentorship and funding channels intended to accelerate product development and validation. The program’s first phase demonstrates the city’s readiness to host a formal accelerator tied to a global pharma company, potentially setting the stage for subsequent cohorts and broader regional growth. (merck.ca)

• With the March 2026 announcement of the second cohort, MDSS Montréal shifts to a nine-month model, expanding the timeline and increasing the number of participating startups to twelve. The longer program duration is designed to deepen engagement, provide more substantial support, and enable more substantive progress toward clinical or regulatory milestones. The cross-border mix of startups indicates that MDSS Montréal aims to catalyze collaboration not only within Canada but across North America, with a clear plan to expand the program’s reach across Canada. (merck.com)

• The second cohort’s participants span a broad set of digital health and biopharma concepts—ranging from AI-driven diagnostics and predictive modeling to advanced cell and gene therapy tooling and translational disease models. The explicit listing of the Canadian and U.S. startups underscores MDSS Montréal’s role as a joint platform that can align cross-border entrepreneurial talent with Merck’s network and ecosystem partners. The program’s structure signals ongoing, staged rounds of intake as Merck continues to invest in digital health accelerator capabilities across North America. (merck.ca)

Key indicators to watch

• Follow-on investments and pilot collaborations: One of the principal metrics for MDSS Montréal will be whether participating startups secure follow-on funding, form strategic partnerships with Merck or-related ecosystem players, or land pilot projects within Merck’s global network. The program’s funding structure, which pairs grants with mentorship and industry exposure, is designed to catalyze such outcomes, and observers will look for tangible pilot announcements or investment rounds in 2026 and beyond. (merck.com)

• Geographic and policy impact: Quebec and broader Canadian policy support for digital health and AI innovation will influence the program’s trajectory. The government’s backing in the initial launch and the ongoing cross-border expansion could inspire similar collaborations in other Canadian regions, potentially attracting more global pharma and tech partnerships to Montréal. Montreal International’s coverage of MDSS’s genesis in Greater Montréal provides a useful lens on regional impact and future opportunities. (montrealinternational.com)

• Ecosystem integration: As MDSS Montréal scales, the depth and breadth of collaboration with Centech, CQDM, TVC, and other ecosystem partners will be telling. The second cohort’s emphasis on connecting Canadian and American startups through a unified program is a strategic move to create an integrated cross-border pipeline for health-tech innovation, a trend that other regions may monitor for replication. (merck.com)

What startups and observers should watch for

• Program outcomes and patient impact: While MDSS Montréal is an accelerator, the ultimate measure will be the extent to which participating startups translate digital biology innovations into clinically meaningful health solutions. Observers should track product milestones, regulatory progress, and any patient-centered outcomes tied to MDSS-supported projects as they emerge in subsequent quarters. The program’s stated focus on preventive health, biologics platforms, and 3D translational disease models is positioned to yield research and clinical translation milestones if startups execute effectively. (merck.ca)

• Cross-border collaboration signals: The North American cohort model signals the potential for a more integrated cross-border health-tech ecosystem. Stakeholders will want to see whether MDSS Montréal spurs joint R&D efforts, pooled funding rounds, or shared pilots across Canada and the United States. Merck executives have framed this expansion as a bridge between innovation communities in two countries, a narrative that industry watchers will be tracking in public disclosures and partner announcements. (merck.com)

• Government and corporate partnership dynamics: The MDSS Montréal program’s success will likely hinge on the alignment of public support, corporate investment, and academic-industrial collaboration. The Quebec government’s funding and the involvement of Centech and CQDM illustrate the model’s reliance on a coordinated ecosystem approach. Observers should monitor continue funding updates, policy shifts, and the emergence of new MDSS-related collaborations as the program matures. (montrealinternational.com)

Closing

The MDSS Montreal expansion represents a concrete step in Merck’s strategy to extend its digital science accelerator footprint beyond the United States and position Montréal as a pivotal node in a North American health-tech corridor. By integrating Canadian and American startups within a unified program, MDSS Montréal seeks to accelerate the translation of AI and digital biology innovations into real-world therapies and health solutions. The program’s early momentum—seven startups in the first cohort and twelve startups in the second—combined with government and ecosystem support, signals a durable commitment to cross-border collaboration and regional leadership in AI-enabled biopharma. As the nine-month cycle for the second cohort unfolds, industry watchers will be looking for demonstrable outcomes—pilot projects, partnerships, and follow-on funding—that validate MDSS Montréal’s model and its potential to reshape how digital health innovations reach patients across North America. (merck.ca)

As Merck’s MDSS program in Montréal continues to evolve, Tech Forum will monitor program milestones, startup progress, and cross-border collaboration indicators to provide data-driven updates on this evolving innovation footprint in Canada and North America. For ongoing coverage, stay tuned to official MDSS releases, Montréal International updates, and independent industry reporting that contextualizes how accelerator programs like MDSS Montréal influence funding dynamics, regulatory timelines, and patient outcomes.